Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): Prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi

Thyroid Research

Volumn 3, Issue 1, 2010, Pages

  Kukulska, Aleksandra ^a   Krajewska, Jolanta ^a   Gawkowska Suwiska, Marzena ^a   Puch, Zbigniew ^a   Paliczka Cieslik, Ewa ^a   Roskosz, Jozef ^a   Handkiewicz Junak, Daria ^a   Jarzab, Micha ^a   Gubaa, Elzbieta ^a   Jarzab, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961143779     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/1756-6614-3-9     Document Type: Article

References (14)

1. 131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W, Eur J of Endocrinol 2005 153 651 9 10.1530/eje.1.02014 (Pubitemid 41672411)
2. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Mazzaferri EL, Thyroid 1997 7 265 71 10.1089/thy.1997.7.265 9133698 (Pubitemid 27190594)
3. Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. McCowen KD, Adler RA, Ghaed N, Verdon T, Hofeldt FD, Am J Med 1976 61 52 8 10.1016/0002-9343(76)90030-9 937370
4. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Bal C, Padhy AK, Jana S, Pant GS, Basu AK, Cancer 1996 77 2574 80 10.1002/(SICI)1097-0142(19960615)77:12<2574::AID-CNCR22>3.0.CO;2-O 8640708
5. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. Johansen K, Woodhouse NJ, Odugbesan O, J Nucl Med 1991 32 252 4 1992028
6. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H, PLoS One 2008 3 1885 10.1371/journal.pone.0001885 18382668 (Pubitemid 351943823)
7. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C, J Clin Endocrinol Metab 2006 91 926 32 10.1210/jc.2005-1651 16384850 (Pubitemid 43357760)
8. Ocena wczesnej skutecznoci leczenia uzupeniajcego izotopem jodu 131 I chorych na zránicowanego raka tarczycy. Gawkowska-Suwiska M, PhD Thesis 2003
9. Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer. Gawkowska-Suwiska M, Turska M, Roskosz J, Puch Z, Jurecka-Tuleja B, Handkiewicz-Junak D, Wygoda Z, Jarzab B, Wiad Lek 2001 54 Suppl 1 278 88 12182036
10. Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi. Kukulska A, Krajewska J, Roskosz J, Handkiewicz-Junak D, Jarzab M, Paliczka E, Puch Z, Wygoda Z, Gubaa E, Jarzab B, Pol J Endocrinol 2006 57 374 379
11. An overview of the management of papillary and follicular thyroid carcinoma. Mazzaferri EL, Thyroid 1999 9 5 421 7 10.1089/thy.1999.9.421 10365671 (Pubitemid 29244917)
12. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC, J Clin Endocrinol Metab 2004 89 3668 76 10.1210/jc.2003-031167 15292285 (Pubitemid 39089119)
13. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Pacini F, Schumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, the European Thyroid Cancer Taskforce, Eur J Endocrinol 2006 154 787 803 10.1530/eje.1.02158 16728537 (Pubitemid 43997716)
14. Diagnostyka I leczenie raka tarczycy. Rekomendacje Polskiej Grupy do spraw Nowotworáw Endokrynnych. Pol J Endocrinol 2010